

Impact of catechin supplementation in older adults with sarcopenia on circulating biomarkers of health status: a systematic review of clinical trials


Fernández-Lázaro D¹, Celorrio A.M.², López Llorente A.¹, Molina A.³, Arribalzaga S.⁴ & Roche E.⁵

¹University of Valladolid, ²University of Leon, ³University Rovira i Virgili, ⁴European University, ⁵Miguel Hernando University

INTRODUCTION & AIM

Sarcopenia is a multifactorial syndrome characterized by musculoskeletal involution with **loss of skeletal and muscle mass, and strength**, leading to dependence, poor quality of life, and mortality. In this respect, nutritional supplementation with antioxidants could mitigate these issues. Therefore, **green tea extract (rich in catechins)** may improve musculoskeletal function by influencing age-related cellular processes, mainly related to oxidative stress. We aimed to evaluate the current evidence in the literature on **catechin supplementation** in older adult patients diagnosed with sarcopenia.

FIGURES & TABLES



PRISMA Flow diagram

METHOD

Rules: PRISMA

Database: Medline, Scopus, CINAHL (from 2007 to 2024).

Quality: McMaster University Occupational Therapy Group.

Risk of bias: Cochrane Tool.

PICOS question

P (population): older adults diagnosed with sarcopenia.

I (intervention): catechin monotherapy treatment.

C (comparison): placebo group, control group, or sham treatment

O (outcome): sarcopenia parameters, health biomarkers, bioavailability, tolerance, and catechins safety.

S (study): randomized controlled trials or not.

RESULTS

Characteristics & interventions

7 Studies included
(randomized controlled trials or not)

Methodological quality: 81,0-93,8%

505 patients with sarcopenia
(320, ♀ and 185 ♂)

Treatment: catechin monotherapy

- ↑* Hematological parameters (↓* leucocytes, 7)
- ↑* Hormonal response (4-7) (↓* myostatin, 7)
- ↑* Anthropometric parameters (1, 3-5, 7) (↑* muscle mass, 1)
- ↑* Physical performance (3-5)
- ↑ Citrate synthase (6) and cytochrome C oxidase } ↑ Mitochondrial function

↑ Increase ↓ Decrease *Statistically significant difference

Study, year	item											Total	Quality	
	1	2	3	4	5	6	7	8	9	10	11			
Aubertin-Leheudre et al., 2007 (1)	+	+	+	+	+	-	-	+	+	+	+	+	9	G
Ide K et al., 2016 (2)	+	+	+	+	+	-	-	+	+	+	+	+	9	G
Kim H et al., 2013 (3)	+	+	+	+	+	+	-	+	+	+	+	+	10	E
Kim H et al., 2016 (4)	+	+	+	+	+	+	-	+	+	+	+	+	10	E
Mafi F et al., 2019 (5)	+	+	+	+	+	+	-	+	+	+	+	+	10	E
McDermott M et al., 2020 (6)	+	+	+	+	+	+	-	+	+	+	+	+	10	E
Seo H et al., 2021 (7)	+	+	+	+	+	+	-	+	+	+	+	+	10	E

Abbreviations: - = criterion not fulfilled; + = criterion fulfilled; E= excellent; G= good

McMaster methodological quality

Study	Random sequence generation	Allocation concealment	Blinding (participants and personnel)	Blinding (outcome assessment)	Outcome data	Selective reporting	Other sources of bias	General risk rating
Aubertin-Leheudre et al., 2007 (1)	+	+	+	?	+	?	+	Yellow
Ide K et al., 2020 (2)	+	+	?	?	+	?	+	Yellow
Kim H et al., 2013 (3)	+	+	+	+	+	?	+	Yellow
Kim H et al., 2016 (4)	+	+	?	?	+	?	+	Yellow
Mafi F et al., 2019 (5)	+	+	+	?	+	?	+	Yellow
McDermott M et al., 2020 (6)	+	+	+	+	+	?	+	Yellow
Seo H et al., 2021 (7)	+	+	+	+	+	?	+	Yellow

Green: minimal risk of bias; Yellow: = risk of bias unclear; Red = high risk of bias.

Cochrane tool of risk of bias

STUDIES ANALYSED

REFERENCES

CONCLUSION

Oral supplementation with catechins improves muscle mass and strength leading to therapeutic benefits in age-related patients with sarcopenia. The anti-inflammatory and antioxidant effect of catechins could be due to the suppression of transcription factor NF- κ B improving the state of skeletal muscle.

